Eight-Year Experience With Botulinum Toxin Type-A Injections for the Treatment of Nonneurogenic Overactive Bladder: Are Repeated Injections Worthwhile?
Shannon Hee Kyung KimDavid HabashySana PathanVincent TseRuth CollinsLewis ChanPublished in: International neurourology journal (2016)
Efficacy is maintained with repeated BTX-A injections. Patients including the elderly show a good degree of tolerability with a low complication rate. Male patients or reduced bladder compliance is associated with poorer outcomes.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- botulinum toxin
- randomized controlled trial
- clinical trial
- type diabetes
- spinal cord injury
- platelet rich plasma
- metabolic syndrome
- patient reported outcomes
- skeletal muscle
- middle aged
- patient reported
- combination therapy